Dr. Hui Wang 王晖
Chief Physician
Department of Thoracic Radiation Oncology I, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Conformal and stereotactic radiotherapy for head, neck, and chest malignancies, including nasopharyngeal cancer, lung cancer, and esophageal cancer.
Dr. Wang is Chief Physician and Director of the Chest Radiotherapy Department at Hunan Cancer Hospital. Holding a clinical oncology doctorate from Xiangya School of Medicine, Dr. Wang completed advanced training in intensity-modulated radiotherapy for head and neck cancers at Sun Yat-sen University Cancer Center in 2005. Visiting scholar positions included Henri Mondor Hospital and Montpellier Cancer Center in France (2009), and MD Anderson Cancer Center in the US (2013), focusing on IMRT, IGRT, and combined chemoradiotherapy for thoracic and head and neck tumors.
Professional roles
- Member, Youth Committee of the Radiation Oncology Branch, Chinese Medical Association
- Member and Secretary, Radiation Oncology Professional Committee, Hunan Branch of the Chinese Medical Association
- Secretary, Hunan Provincial Tumor Radiotherapy Quality Control Center
Name order: in Chinese the family name comes first (Wang Hui). Papers usually list the name as Hui Wang or Wang H.
Selected publications
143 papers on PubMed matched by name and affiliation; 22 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Exp Clin Cancer Res, 2026 (senior author): Cholesterol metabolism reprogramming: shaping tumor immunity and immunotherapy. PubMed 42934700
- Int J Oncol, 2026 (senior author): mTOR in radiotherapy of lung cancer: Mechanisms of radiation resistance and therapeutic implications (Review). PubMed 41384305
- Exp Mol Med, 2025 (senior author): Author Correction: Notch1 promotes the pericyte-myofibroblast transition in idiopathic pulmonary fibrosis through the PDGFR/ROCK1 signal pathway. PubMed 40555743
- BMC Cancer, 2025 (senior author): Reirradiation based on diffusion-weighted magnetic resonance imaging-guided dose- painting for locally advanced recurrent nasopharyngeal carcinoma: a phase 2 randomized controlled trial. PubMed 40197313
- Med, 2024 (first author): Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer. PubMed 38964333
- Sci Rep, 2023 (senior author): Identify and validate circadian regulators as potential prognostic markers and immune infiltrates in head and neck squamous cell carcinoma. PubMed 37968308
- Int Immunopharmacol, 2023 (senior author): ACSL4 promotes ferroptosis and M1 macrophage polarization to regulate the tumorigenesis of nasopharyngeal carcinoma. PubMed 37451020
- Cancer Cell Int, 2022 (senior author): Role of HOXA9 in solid tumors: mechanistic insights and therapeutic potential. PubMed 36376832
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion